Cancer Vaccine for Chronic Lymphocytic Leukemia
Trial Summary
What is the purpose of this trial?
This trial studies a special vaccine made from a patient's own cancer cells and an immune booster to treat chronic lymphocytic leukemia. It targets patients who have not been treated before, aiming to help their immune system recognize and destroy cancer cells.
Research Team
Shuo Ma, MD, PhD
Principal Investigator
Northwestern University
Eligibility Criteria
Adults with untreated chronic lymphocytic leukemia (CLL) showing disease progression but not severe enough to require immediate treatment. Participants must have a certain level of white blood cells, be in good physical condition, and have normal kidney and liver function. Women who can bear children and sexually active men must use contraception. Those with other cancers, immune diseases, or infections that could affect the trial are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Oncoquest-CLL vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
XEME Biopharma Inc.
Lead Sponsor
National Cancer Institute (NCI)
Collaborator